No Data
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349) and its subsidiary Taizhou Fudan-Zhangjiang and Shanghai Source Biotechnology have received a total of 31.1363 million yuan in government subsidies.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349) announced that the company and its subsidiary Taizhou Fudan-Zhangjiang Pharmaceutical Co. Ltd. (hereinafter referred to as...)
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Zhitong Hong Kong Stock Shareholder Equity Disclosure | December 11
Disclosure of shareholder equity in Hong Kong stocks | December 11.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hong Kong Stock Exchange Exploration | Healthy World Technology-B: LuX-Valve Plus TRAVEL II one-year clinical follow-up results to be released at the 2024 American Washington Congress of Cardiology through the catheter.
CH Energy Eng (03996) controlling shareholder received financial support for shareholding in A shares; following Takeda's FRUQUINTINIB (呋喹替尼/fruquintinib) sales exceeding 0.2 billion US dollars, Hutchmed (China) (00013) will receive the first milestone payment.
No Data